“…Ropinirole acted as, albeit a weak, reinforcer in nonhuman primates (Freeman, Heal, McCreary, & Woolverton, 2012), which partly supports clinical data, suggesting that ropinirole marginally reduced craving in humans (Meini et al, 2012) and reduced the subjective intensity for the "cocaine rush" (Maremmani et al, 2011). Treatment with another dopamine D 2 agonist, pramipexole, caused perseverated responding in a reversal learning task, which was associated with stimulant dependence, rather than compulsive measures, suggesting additional efficacy for the potential treatment of SUD (Ersche et al, 2011). Together, these data support the dopamine replacement hypotheses, suggesting that clinically approved dopaminomimetic compounds might have clinical utility.…”